Association of IL28B (IFNL3) rs12979860 mRNA levels, viral load and liver function among HCV genotype 1a infection patients: a cross-sectional study in iranian patients
Gastroenterology and Hepatology from Bed to Bench,
Aim: The present study was designed to evaluate the correlation of interleukin 28B (IL28B, IFNL3) rs12979860 mRNA levels, viral load, and liver function among hepatitis C virus (HCV) patients genotype 1a.
Background: HCV is considered essentially hepatotropic and is a major health problem around the world.
Methods: This study included 100 HCV-infected patients with HCV genotype1a (G1a) and rs12979860 CC genotype. These patients were divided into two groups according to HCV treatment. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and HCV Load were measured and recorded for each patient. IL28B mRNA levels were determined using real-time polymerase chain reaction assay, and their correlation with clinical data were analyzed. STRING was applied to construct a network and identify interactions between IL28B (IFNL3) and its significant neighbor proteins.
Results: The results revealed a significant relationship between the ALT as well as ALP levels with IL28B rs12979860 mRNA expression level in men, and also with age >50 years. In the treated group, AST level and HCV load had a significant relationship with IL28B mRNA expression level. The results showed that the level of ALP and AST decreased significantly with increased IL28B mRNA expression level in the treated and untreated group, respectively. STRING database showed that IL28B (IFNL3) interacted with ten important neighbor proteins with some of these proteins being involved in signal transduction pathway activating antiviral response.
Conclusion: This study indicated that rs12979860CC genotype could predict IL28B mRNA expression level in HCV-infected patients with G1a. Furthermore, IL28B mRNA expression level may serve as a useful marker for the development of G1a HCV-associated outcomes.
Keywords: HCV patients, Interleukin 28B, IFNL3, mRNA levels, Liver enzyme.
(Please cite as: Mousavi Nasab SD, Ahmadi Vasmehjani A, Kaghazian H, Mardani R, Zali F, Ahmadi NA, et al. Association of IL28B (IFNL3) rs12979860 mRNA levels, viral load and liver function among HCV genotype 1a patients. Gastroenterol Hepatol Bed Bench 2019;12(Suppl.1):S156-S162).
- HCV patients
- Interleukin 28B
- mRNA levels
- Liver enzyme
How to Cite
Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections.J hepatol 2014;61(1):S14-S25.
DDustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection—tipping the balance. J Leukoc Biol 2014;96(4):535-48.
Alexopoulou A, Karayiannis Peter. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol 2015;28(1):55–65.
Tsubota A, Fujise K, Namiki Y, Tada N. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 2011;2(1):39-45.
Yan Z, Wang Y. Viral and host factors associated with outcomes of hepatitis C virus infection. Mol Med Rep 2017;15(5):2909-24.
Mousavi Nasab SD, Baharlou R, Piroozmand A, Toghyani H, Shadmand E, Fazel H, et al. Distribution of IL-28B genotypes in patients with hepatitis C and healthy individuals in Jahrom city. Gastroenterol Hepatol Bed Bench 2015;8(4): 278–287.
Chinnaswamy S. Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions. J Interferon Cytokine Res 2014;34(7):479-97.
Shi X, Pan Y, Wang M, Wang D, Li W, Jiang T, et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 2012;7(5):e37054.
Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012;57(5):1110-25.
Hafez AA, Vasmehjani AA, Baharlou R, Nasab SDM, Davami MH, Najafi A, et al. Analytical assessment of interleukin-23 and-27 cytokines in healthy people and patients with hepatitis C virus infection (genotypes 1 and 3a). Hepat Mon 2014;14(9).
Behzadpour D, Ahmadi Vasmehjani A, Mousavi Nasab SD, Ahmadi NA, Baharlou R. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes. Pathog Glob Health 2016;110(7-8):310–5.
Ignatieva EV, Igoshin AV, Yudin NS. A database of human genes and a gene network involved in response to tick-borne encephalitis virus infection. BMC Evol Bio. 2017;17(2):259.
Indolfi G, Azzari C, Resti M. Polymorphisms in the IFNL3/IL28B gene and hepatitis C: from adults to children. World J Gastroenterol 2014;20(28):9245-52.
Daneshvar M, Nikbin M, Talebi S, Javadi F, Aghasadeghi MR, Mahmazi S, et al. Role of IL28-B polymorphism (rs12979860) on sustained Virological response to Pegylated interferon/ribavirin in Iranian patients with chronic hepatitis C. Iran Red Crescent Med J 2016;18(9):e28566.
Sarvari J, Mansouri M, Hashempoor T, Hosseini SY, Moattari A, Pirbonyeh N, et al. Association of genotype and haplotype of IL-28B Gene with Hepatitis C infection outcome in iran: Spontaneous clearance versus chronic infection. Hepat Mon 2017;17(5):e45745.
Hafez AA, Baharlou R, Nasab SDM, Vasmehjani AA, Shayestehpour M, Joharinia N, et al. Molecular epidemiology of different hepatitis C genotypes in serum and peripheral blood mononuclear cells in jahrom city of iran. Hepat Mon 2014;14(5):e16391.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible.Nucleic Acids Res2017;4;45(D1):D362-D368.
Pagliaccetti NE, Robek MD. Interferon-λ in HCV infection and therapy. Viruses 2010;2(8):1589-602.
Huang M, Jiang JD, Peng Z. Recent advances in the anti-HCV mechanisms of interferon. Acta Pharm Sin B 2014;4(4):241-7.
Bruening J, Weigel B, Gerold G. T. The role of type III interferons in hepatitis C virus infection and therapy. J Immunol Res 2017;2017:7232361.
Hendy O, Moneam E, Shafie M, Elsabaawy M, Rady M, Baz S. Role of IL28B Gene Polymorphisms in Response to the Standard of Care Treatment in Egyptian Patients with Chronic HCV Genotype Four. Life Sci J. 2011;8:908-15.
Khairy M, Fouad R, Mabrouk M, El-Akel W, Awad AB, Salama R, et al. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysis. Hepat Mon 2013;13(7):e10509.
Li Y, Wei T, Yan L, Yang Z, Huang Q, Shi Y, et al. Association of interleukin-28B polymorphisms with platelet count and liver function recovery after liver transplant. Medicine (Baltimore) 2017;96(44):e8219.
Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011;54(6):1094-101.
Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, et al. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res 2015;2015:768470.
Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol (Baltimore, Md : 1950). 2005;174(4):1932-7.
Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. JGene Virol. 2008;89(Pt 1):1-47.
- Abstract Viewed: 101 times
- PDF Downloaded: 38 times